

Poly Medicure Limited

Regd. Office : 232-B, 3rd Floor, Okhla Industrial Estate,
Phase-III, New Delhi - 110020 (INDIA)
T: +91-11-33550700, 47317000, F: +91-11-26321894, 26321839
E: info@polymedicure.com W: polymedicure.com
CIN: L 40300DL1995PLC066923



Date: 13th May, 2022

Scrip Code: - 531768

Scrip Code:- POLYMED

The Manager,
BSE Limited,
Department of Corporate Services,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

The Manager
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1-Block-G
Bandra Kurla Complex, Bandra(E),
Mumbai-400051.

Subject: Reporting of Annual Disclosure to be made by entity as per Large Corporate criteria

Dear Sir/Madam,

Further to our Corporate Announcement dated April 30, 2022 and pursuant to SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, please find enclosed our annual disclosure submission in the prescribed format.

This is for your information and records.

Kindly take a note of the same for your further needful and oblige us.

Thanking You,

Yours Sincerely

For Poly Medicure Limited


Avinash Chandra
Company Secretary



Encl: Annexure B2

Poly Medicure Limited

Regd. Office : 232-B, 3rd Floor, Okhla Industrial Estate,
Phase-III, New Delhi - 110020 (INDIA)
T: +91-11-33550700, 47317000, F: +91-11-26321894, 26321839
E: info@polymedicure.com W: polymedicure.com
CIN: L 40300DL1995PLC066923



Annexure B2

**Format of the Annual Disclosure to be made by an entity identified as a LC
(To be submitted to the Stock Exchange(s) within 45 days of the end of the FY)
(Applicable from FY 2022 onwards)**

1. Name of the Company : Poly Medicure Limited
2. CIN : L40300DL1995PLC066923
3. Report filed for FY : 2021-22 (T) : 2021-22
4. Details of the Current block (all figures in Rs. Crore) :

S. No.	Particulars	Details
i.	2-year block period (Specify financial years)	T: FY 2021-22 T+1: FY 2022-23
ii.	Incremental borrowing done in FY (T) (a)	0.00
iii.	Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)	NA
iv.	Actual borrowing done through debt securities in FY (T) (c)	NA
v.	Shortfall in the borrowing through debt securities, if any, for FY (T-1: FY 2020-21) carried forward to FY (T). (d)	NA
vi.	Quantum of (d), which has been met from (c) (e)	NA
vii.	Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) {after adjusting for any shortfall in borrowing for FY (T-1: FY 2020-21) which was carried forward to FY (T)} (f) = (b) - [(c) - (e)] {If the calculated value is zero or negative, write "nil"}	Nil



Poly Medicure Limited

Regd. Office : 232-B, 3rd Floor, Okhla Industrial Estate,
Phase-III, New Delhi - 110020 (INDIA)
T: +91-11-33550700, 47317000, F: +91-11-26321894, 26321839
E: info@polymedicure.com W: polymedicure.com
CIN: L 40300DL1995PLC066923





5. Details of penalty to be paid, if any, in respect to previous block (all figures in Rs Crore):

S. No.	Particulars	Details
i.	2-year Block period (Specify financial years)	T: FY 2021-22 T+1: FY 2022-23
ii.	Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d)-(e)}	NA



Avinash Chandra
Company Secretary
Contact Details: 011-33550700



Naresh Vijayvergiya
Chief Financial Officer
0129-3355070

Date: 13.05.2022